Datopotamab deruxtecan in EGFR-mutated lung cancer: an exciting new option

Introduction

The management of advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) has been transformed by the development of increasingly potent tyrosine kinase inhibitors (TKIs). Agents such as osimertinib and amivantamab have demonstrated high response rates and substantial survival benefits and are now established as standards of care in both first-line and subsequent treatment settings (1,2). Despite these advances, acquired resistance to EGFR-TKIs remains inevitable for most patients, reflecting the biological complexity and heterogeneity of EGFR-mutated tumors.

Following progression on EGFR-TKIs and platinum-based chemotherapy, therapeutic options are limited. Docetaxel, with or without antiangiogenic agents, remains the most commonly used treatment in this setting, but has modest efficacy and considerable toxicity (3). Immune checkpoint inhibitors have shown limited activity in EGFR-mutated NSCLC, further underscoring the unmet need for novel therapeutic strategies (4).

Antibody drug conjugates (ADCs) have emerged as a promising therapeutic class. The pooled analysis of the TROPION-Lung 05 and TROPION-Lung 01 trials by Ahn et al. evaluating datopotamab deruxtecan (dato-DXd) in patients with EGFR-mutated NSCLC provides important insights into the potential role of this agent in a population with few effective treatment options (5).

Rationale for dato-DXd

Dato-DXd is a trophoblast cell surface antigen 2 (TROP2) directed ADC composed of a humanized monoclonal antibody linked to a potent topoisomerase I inhibitor payload (DXd). TROP2 is highly expressed across epithelial malignancies, including NSCLC, particularly in non-squamous histologies where EGFR mutations are most prevalent (6).

The rationale for using dato-DXd in EGFR-mutated NSCLC is multifaceted. First, TROP2 expression appears to be largely maintained despite the development of resistance to EGFR-TKIs (7) Second, unlike TKIs which depend on inhibiting specific intracellular signaling pathways ADCs deliver a cytotoxic payload directly to tumor cells, thereby bypassing many common resistance mechanisms, including secondary EGFR mutations, MET amplification, and pathway redundancy.

Advanced EGFR-mutated NSCLC is characterized by marked heterogeneity (8,9). Tumors often comprise multiple subclonal populations, each with distinct resistance mechanisms. Traditional targeted therapies may eliminate only mutation dependent clones, allowing resistant cells to persist and drive disease progression. Once Dato-DXd is internalized into a TROP2-expressing cell, intracellular cleavage releases the deruxtecan payload, which can diffuse into adjacent tumor cells, generating a bystander effect (10). This property may be particularly advantageous in heterogeneous, heavily pretreated tumors, and likely contributes to the depth and durability of responses observed in the TROPION studies.

Overview of the pooled analysis

The pooled analysis by Ahn et al. (5) integrates data from the phase II TROPION-Lung05 (11) and phase III TROPION-Lung01 (12) trials. The analysis included 117 patients with advanced or metastatic EGFR-mutated NSCLC who had progressed following EGFR-targeted therapy and platinum-based chemotherapy. This was a heavily pretreated cohort, with a median of three prior lines of systemic therapy.

Most patients had non-squamous histology, and approximately one-third had treated or asymptomatic brain metastases, an important subgroup often underrepresented in clinical trials. The distribution of EGFR mutations reflected known epidemiology, with exon 19 deletions and L858R substitutions predominating. The T790M resistance mutation was present in a minority of patients, reflecting prior exposure to osimertinib in most cases.

The confirmed objective response rate (ORR) by blinded independent central review was 42.7%, including five complete responses. The disease control rate was 86.3%. Median progression-free survival (PFS) was 5.8 months, and median overall survival (OS) was 15.6 months.

Strengths and clinical relevance

The efficacy observed in this pooled analysis is particularly notable given the refractory nature of the study population. Importantly, clinical activity was maintained in patients previously treated with osimertinib, with an ORR of 44.8% and durability of response (DOR) of 6.9 months in this subgroup. These findings are highly relevant, as osimertinib is now widely used in the frontline setting. Moreover, responses were observed across EGFR mutation subtypes, suggesting that TROP2-directed therapy may function as a mutation-agnostic strategy once EGFR-driven dependence is lost.

When placed in historical context, the outcomes with Dato-DXd compare favorably with docetaxel-based therapy, which according to the existing literature yields ORRs of 10–15% and limited durability in the post-TKI setting (3). In this analysis, docetaxel-based therapy ORR was 9% with DOR of only 3.6 months.

From a safety perspective, Dato-DXd demonstrated a manageable and predictable toxicity profile consistent with prior ADC studies. Grade 3 or higher treatment-related adverse events occurred in approximately 23% of patients. The toxicity spectrum differed from that of conventional chemotherapy (docetaxel), with stomatitis, mucositis, and interstitial lung disease (ILD) or pneumonitis being most significant. While hematologic toxicity appeared less pronounced than with docetaxel, clinicians must remain vigilant for ADC-specific adverse events, particularly pulmonary toxicity, which requires early recognition and prompt management.

Limitations

Several limitations warrant consideration. The absence of a randomized comparator arm limits direct comparison with standard therapies and other emerging ADCs. Additionally, the pooled nature of the analysis introduces heterogeneity related to study design, prior therapies, and resistance mechanisms.

Thirdly, the analysis was not powered to identify predictive biomarkers of response, and the relationship between TROP2 expression levels and clinical benefit remains unclear. Nevertheless, the use of blinded independent central review and consistent dosing across studies enhances the robustness of the reported outcomes.

Clinical and translational implications

This analysis highlights Dato-DXd as a clinically meaningful option for patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy. The combination of meaningful efficacy, mutation-agnostic activity, and manageable toxicity supports its further development in this population.

From a translational standpoint, the findings underscore the importance of targeting tumor heterogeneity and resistance through novel mechanisms of action. ADCs such as Dato-DXd may represent a critical bridge between targeted therapy and cytotoxic chemotherapy in EGFR-mutated disease.

Future directions

Several key questions remain. Identifying patients most likely to benefit from Dato-DXd is a priority, including clarification of the role of TROP2 expression as a predictive biomarker. Treatment sequencing is becoming increasingly complex with the emergence of agents such as amivantamab-based combinations and other novel ADCs (13).

Beyond monotherapy, the focus has shifted toward synergistic combinations to overcome resistance and improve duration of response. The TROPION-Lung14 trial evaluates Dato-DXd in combination with osimertinib vs. osimertinib monotherapy in the first line setting, seeking to delay resistance by pairing targeted inhibition of the EGFR pathway with a cytotoxic payload from the start. The TROPION-Lung15 trial explores Dato-DXd either as monotherapy or with osimertinib vs. platinum doublet chemotherapy in patients who have already progressed on third generation TKIs. These trials will help define the role of Dato-DXd in earlier lines of therapy and in combination strategies.

While the current analysis focuses on the EGFR-mutated population, the broader TROPION clinical program is evaluating Dato-DXd in the non-actionable genomic alteration setting as well. For instance, TROPION-Lung07 and TROPION-Lung08 are investigating Dato-DXd in combination with the anti-PD-1 inhibitor pembrolizumab, with or without platinum-based chemotherapy, as a first-line strategy. These studies aim to redefine the standard of care across different PD-L1 expression levels, further establishing the versatility of TROP2-directed ADCs as a backbone for combination therapy in NSCLC.

Real-world evidence and long-term safety monitoring will also be essential as Dato-DXd moves closer to routine clinical use.

Conclusions

The pooled analysis of the TROPION-Lung05 and TROPION-Lung01 trials provides compelling evidence that datopotamab deruxtecan offers clinically meaningful activity in a heavily pretreated population of patients with EGFR-mutated NSCLC. In a therapeutic landscape characterized by limited options following EGFR-TKI resistance, Dato-DXd demonstrates response rates and survival outcomes that compare favorably with historical standards while maintaining a manageable safety profile.

Although confirmatory randomized studies and biomarker-driven refinement are still needed, these findings support Dato-DXd as a promising addition to the evolving treatment paradigm of EGFR-mutated NSCLC. As ADCs continue to reshape thoracic oncology, datopotamab deruxtecan represents an important step toward addressing the unmet needs of patients with treatment-resistant disease.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Shanghai Chest. The article has undergone external peer review.

Peer Review File: Available at https://shc.amegroups.com/article/view/10.21037/shc-2026-1-0004/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://shc.amegroups.com/article/view/10.21037/shc-2026-1-0004/coif). A.K.G. received contract to institution from Apexigen, NEKTAR Pharmaceuticals, Merck, Pfizer, Boehringer Ingelheim, Poseida Inc, Mirati Therapeutics and Imugene. A.K.G. received consulting fees from AstraZeneca, Cardinal Health, Jazz Pharmaceuticals, Pfizer, Zai Labs, Catalyst Pharmaceuticals, Amgen, Regeneron Pharmaceuticals, Fosun Pharma, Boehringer Ingelheim, EMD Serono and Sanofi Genzyme. A.K.G. declares receipt of drug from Chimerix. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. [Crossref] [PubMed]
2. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50. [Crossref] [PubMed]
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. [Crossref] [PubMed]
4. Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—A meta-analysis. J Thorac Oncol 2017;12:403-7. [Crossref] [PubMed]
5. Ahn MJ, Lisberg A, Goto Y, et al. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol 2025;20:1669-82. [Crossref] [PubMed]
6. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018;9:28989-9006. [Crossref] [PubMed]
7. Zeng L, Zhu Y, Moreno CS, et al. New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy. Clin Cancer Res 2022;28:3691-702.
8. Zhu VW, Zhang J, Schrock AB, et al. EGFR-mutant lung cancers exhibit marked heterogeneity in their genomic landscapes and clinical responses to therapy. Cancer Med 2024;13:e6942.
9. Blakely CM, Watkins TBK, Yumwuan V, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 2017;49:1693-704. [Crossref] [PubMed]
10. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097-108. [Crossref] [PubMed]
11. Sands J, Ahn MJ, Lisberg A, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol 2025;43:1254-65. [Crossref] [PubMed]
12. Ahn MJ, Tanaka K, Paz-Ares LTROPION-Lung01 Trial Investigators, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol 2025;43:260-72. [Crossref] [PubMed]
13. Besse B, Goto K, Wang Y, et al. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A. J Thorac Oncol 2025;20:651-64. [Crossref] [PubMed]